LGND — Ligand Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $1.44bn
- $1.27bn
- $131.31m
- 76
- 35
- 95
- 77
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 120 | 186 | 277 | 196 | 131 |
Cost of Revenue | |||||
Gross Profit | 109 | 156 | 215 | 143 | 121 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | -687 | 161 | 206 | 189 | 119 |
Operating Profit | 807 | 25.8 | 71.6 | 7.24 | 11.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 797 | -10.5 | 47.3 | 36 | 63.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | 629 | -2.98 | 57.1 | -5.22 | 53.8 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 629 | -2.98 | 57.1 | -33.4 | 52.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 629 | -2.98 | 57.1 | -33.4 | 52.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 5.11 | -0.04 | 3.59 | -0.471 | 2.93 |